笼状二聚体4-芳基-1,4-二氢吡啶作为开发新型HIV-1蛋白酶抑制剂的有前景的先导结构。 - Suppr | 超能文献

Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors.

作者信息

Hilgeroth A, Billich A

机构信息

Institut für Pharmazeutische Chemie der Martin-Luther-Universität Halle-Wittenberg, Germany.

出版信息

Arch Pharm (Weinheim). 1999 Jan;332(1):3-5. doi: 10.1002/(sici)1521-4184(19991)332:1<3::aid-ardp3>3.0.co;2-1.

DOI:10.1002/(sici)1521-4184(19991)332:1<3::aid-ardp3>3.0.co;2-1

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors.笼状二聚体4-芳基-1,4-二氢吡啶作为开发新型HIV-1蛋白酶抑制剂的有前景的先导结构。

Arch Pharm (Weinheim). 1999 Jan;332(1):3-5. doi: 10.1002/(sici)1521-4184(19991)332:1<3::aid-ardp3>3.0.co;2-1.

2

Cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines as first representatives of a novel class of HIV-1 protease inhibitors.笼状二聚体N-酰基-和N-酰氧基-4-芳基-1,4-二氢吡啶作为一类新型HIV-1蛋白酶抑制剂的首个代表物。

Arch Pharm (Weinheim). 1999 Nov;332(11):380-4. doi: 10.1002/(sici)1521-4184(199911)332:11<380::aid-ardp380>3.0.co;2-t.

3

Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors--affinities to intestinal P-glycoprotein.二聚体4-芳基-1,4-二氢吡啶作为新型HIV-1蛋白酶抑制剂——对肠道P-糖蛋白的亲和力

Pharmazie. 2000 Oct;55(10):784-5.

4

Synthesis and biological evaluation of the first N-alkyl cage dimeric 4-aryl-1,4-dihydropyridines as novel nonpeptidic HIV-1 protease inhibitors.首个 N-烷基笼状二聚体 4-芳基-1,4-二氢吡啶作为新型非肽类 HIV-1 蛋白酶抑制剂的合成及生物学评价

J Med Chem. 1999 Nov 4;42(22):4729-32. doi: 10.1021/jm991115k.

5

Design and synthesis of novel conformationally restricted HIV protease inhibitors.

Bioorg Med Chem Lett. 1998 Dec 15;8(24):3637-42. doi: 10.1016/s0960-894x(98)00670-2.

6

[Current status of HIV protease inhibitors].[HIV蛋白酶抑制剂的现状]

Yao Xue Xue Bao. 2005 May;40(5):389-94.

7

New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.新型氮杂二肽类似物作为强效且口服吸收的HIV-1蛋白酶抑制剂：临床开发候选药物

J Med Chem. 1998 Aug 27;41(18):3387-401. doi: 10.1021/jm970873c.

8

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.作为HIV-1蛋白酶抑制剂的非肽环氰基胍：合成、构效关系及X射线晶体结构研究

J Med Chem. 1998 Apr 23;41(9):1446-55. doi: 10.1021/jm970524i.

9

Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.设计、不对称合成及假对称亚砜亚胺类 HIV-1 蛋白酶抑制剂的评价。

Bioorg Med Chem. 2010 Mar 1;18(5):2037-48. doi: 10.1016/j.bmc.2010.01.020. Epub 2010 Jan 21.

10

Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.

J Med Chem. 2000 Sep 21;43(19):3495-504. doi: 10.1021/jm000013n.

引用本文的文献

1

DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway.DDTC 通过 PI3K/AKT/mTOR 信号通路抑制卵巢癌的发展。

Dis Markers. 2022 Aug 8;2022:1941077. doi: 10.1155/2022/1941077. eCollection 2022.

2

6,12-Diphenyl-3, 9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate Inhibits Proliferation, Migration and Promotes Apoptosis in Ovarian Cancer Cells.6,12-二苯基-3,9-二氮杂四环[3.3.1.13,7]癸烷-1,5,7,11-四羧酸酯抑制卵巢癌细胞的增殖、迁移并促进其凋亡。

Dis Markers. 2020 Sep 3;2020:5068067. doi: 10.1155/2020/5068067. eCollection 2020.